Dong Wha Pharm signs export agreement of USD 32 million for ‘Zabolante’
Dong Wha Pharm(Chairman Do-Joon Yoon) signed a license and supply agreement of the quinolone-type antibody ‘Zabolante,’ the Korea’s 23rd new drug, to commercialize in 12 countries, like the Middle East and North Africa.
The agreement contains a term to assign the exclusive sales license in 12 ME...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
